Home » Anti-epileptic Drugs Market

Anti-epileptic Drugs Market By Drug Class (Hydantoin derivatives, Iminostilbenes, Long acting barbiturates, Succinimides, Benzodiazepines, Carbonic anhydrase inhibitors (CAI), GAMA- vinyl – GABA, Amino acid derivatives, Monosaccharide derivatives, Others : Valproic acid derivatives, Deoxy barbiturate, Phenyltriazine, Nicotinic acid derivatives, Sulphonamide derivatives) – Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Price: $4999

Published: | Report ID: 12779 | Report Format : PDF


Market Insights

Epilepsy is a neurological disorder in which patients experience epileptic seizures. These epileptic seizures are a result of a disturbance in the electrical communication in neurons. Seizures can vary from short periods to long episodes of vigorous shaking. Only after one or more seizure episodes can a patient be diagnosed with epilepsy. Patients may have more than one type of seizure, and these seizures usually follow the same pattern each time they occur. Causes of epilepsy include the patient’s genetics, a tumor, or brain injuries. Epileptic seizures are of two types, i.e., focal and generalized, depending on the affected area of the brain. Symptoms that occur before seizures include nausea, headache, strange feelings, and visual loss. Anti-epileptic drugs are used to treat this neurological disorder.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

This market analysis report on the anti-epileptic drug market provides a detailed analysis of the market. This report explains key market trends and aids industry leaders in their strategic initiatives and decision-making. The report provides market value and forecasts for the anti-epileptic drug market.

The scope of the report comprises a demarcation of the market in terms of drug class and geographical distribution. The drug class segments are further categorized into hydantoin derivatives, iminosilbenes, long-acting barbiturates, succinimides, benzodiazepines, carbonic anhydrase inhibitors (CAI), GAMA-vinyl-GABA, amino acid derivatives, monosaccharide derivatives, and others. Others include valproic acid derivatives, deoxybarbiturate, phenyltriazine, nicotinic acid derivatives, and sulphonamide derivatives. Each segment is analyzed considering market drivers and restraints for the market value of the anti-epileptic drugs market. CAGRs are provided for the forecast year 2017–2025 for each segment.

Based on geographical demarcation, the report provides an analysis of the following geographical segments along with major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The market estimation is also elucidated for the above-mentioned segments of the anti-epileptic drugs market. This regional market estimation is proved granularly by segmenting the regions by drug class and country. CAGRs are calculated for the forecast year of 2017–2025.

This report provides key insights about the global anti-epileptic drugs market, including market drivers & restraints, key trends, opportunities, and a regional outlook. Analysis tools such as Porter’s five forces and competitive landscape analysis are also incorporated in this report. Leading players in the global anti-epileptic market are also profiled in this report. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp., Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., and UCB Pharma.

A complete description of the market dynamics is also presented in the report to help understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiles of the major market players that hold prominent positions in the anti-epileptic drugs market globally. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp., Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., and UCB Pharma.

Based on the drug class, the global anti-epileptic drugs market is segmented as follows:

  • Hydantoin derivatives
  • Iminostilbenes
  • Long-acting barbiturates
  • Succinimides
  • Benzodiazepines
  • Carbonic anhydrase inhibitors (CAI)
  • GABA; GAMA-vinyl
  • Amino acid derivatives
  • Monosaccharide derivatives
  • Others
  • Valproic acid derivatives
  • Deoxy barbiturate
  • Phenyltriazine
  • Nicotinic acid derivatives
  • Sulphonamide derivatives

Anti-epileptic drugs are classified based on the drug class. Each drug class has a different mechanism of action for the treatment of epilepsy. Because of the difference in mechanism of action, the drug’s prescription is determined by the type of seizures experienced by the patients. Most of the drugs are used as monotherapy and for partial-onset seizures. Succinimide, hydantoin derivatives, and benzodiazepines are mostly preferred by doctors. Vimpat, Fycompa, Lacosamide, and Retigabine are some of the anti-epileptic drugs preferred by physicians.

Increasing awareness about treatment with anti-epileptic drugs, patent expiration, and the approval of pipeline products are the factors responsible for the market’s growth. The global anti-epileptic drugs market is emerging at a considerable pace because of the high prevalence of epilepsy and the increased research and development activities involved.

Geographically, the global anti-epileptic drug market is cumulative for Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America.

According to the estimation for the year 2016, North America dominated the global anti-epileptic drugs market by accounting for a major share of the market. In terms of market share, North America is followed by Europe. Increased healthcare expenditure, government initiatives, and approval of new drugs are the prime factors regulating the market in these regions. For instance, a few years back, Eisai Co. Ltd. launched Fycompa in the Americas and Europe. Other factors for the market’s growth in this region include the high prevalence of epilepsy and the presence of treatment options in the region. According to the research, there are around 2.5 million cases of epilepsy in the U.S., and around 15,000 new cases of epilepsy are diagnosed each year in Canada. In terms of market value, Europe is followed by Asia-Pacific. The high prevalence of epilepsy in China and India and increased awareness of epilepsy are some of the major factors responsible for the anti-epileptic drug market growth.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

The detailed geographical classification of the global anti-epileptic drug market is as follows:

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, and the Rest of Asia Pacific)
  • Europe (Germany, U.K., and the Rest of Europe)
  • Latin America (Mexico, Brazil, and the Rest of Latin America)
  • Middle East and Africa (GCC plus the rest of the Middle East and Africa)

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Anti-epileptic Drugs Market Portraiture
2.1.1. Global Anti-epileptic Drugs Market, by Drug Class, 2016 (US$ Mn)
2.1.2. Global Anti-epileptic Drugs Market, by Geography, 2016 (US$ Mn)

Chapter 3. Anti-epileptic Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Epilepsy: Epidemiology
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2016
3.7. Value Chain Analysis
3.8. Major Agreements, Partnerships and Collaborations
3.9. Competitive Landscape
3.9.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Anti-epileptic Drugs Market, by Drug Class, 2015-2025 (US$ Mn)
4.1. Overview
4.1.1. Attractive Investment Proposition, by Drug Class, 2016
4.2. Hydantoin derivatives
4.2.1. Phenytoin
4.2.2. Fosphenytoin
4.3. Iminostilbenes
4.3.1. Carbamazepine
4.3.2. Oxcarbazepine
4.4. Long acting barbiturates
4.4.1. Phenobarbitone
4.4.2. Methobarbitone
4.5. Succinimides
4.5.1. Ethosuximide
4.5.2. Methsuximide
4.5.3. Phensuximide
4.6. Benzodiazepines
4.6.1. Clonazepam
4.6.2. Nitrazepam
4.6.3. Diazepam
4.7. Carbonic anhydrase inhibitors (CAI)
4.7.1. Acetazolamide
4.7.2. Sulthiame
4.8. GAMA- vinyl – GABA
4.8.1. Vigabatrin
4.9. Amino acid derivatives
4.9.1. GABA pentin
4.10. Monosaccharide derivatives
4.10.1. Topiramate
4.11. Others (Valproic acid derivatives, Deoxy barbiturate, Phenyltriazine, Nicotinic acid derivatives and Sulphonamide derivatives)
4.12. Phase III (Market estimations by 2025)
4.12.1. Brivaracetam or ucb 34714 (UCB Pharma)
4.12.2. Topiramate (Janssen Research & Development, LLC)
4.12.3. Levetiracetam (Janssen Research & Development, LLC)
4.12.4. Others
4.13. Tabular Presentation of Phase II (Qualitative Information)
4.14. Tabular Presentation of Phase Phase I (Qualitative Information)

Chapter 5. Global Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.2.1. North America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.2.2. North America Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.3.1. Europe Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.3.2. Europe Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.4.1. Asia Pacific Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of APAC
5.5. Latin America Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.5.1. Latin America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.6.1. MEA Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.6.2. MEA Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Abide Therapeutics
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Application Portfolio
6.1.4. Key Developments
6.2. Advicenne Pharma SA
6.3. Alexza Pharmaceuticals
6.4. Argentum Pharmaceuticals
6.5. GlaxoSmithKline (GSK) plc
6.6. GW Pharmaceuticals Plc
6.7. Janssen Pharmaceuticals
6.8. Marinus Pharmaceuticals
6.9. Novartis Pharmaceuticals Corp
6.10. Otsuka Pharmaceuticals
6.11. Pfizer Inc.
6.12. Takeda Pharmaceutical Company Ltd
6.13. UCB Pharma

List of Figures

FIG. 1 Anti-epileptic Drugs: Market Segmentation
FIG. 2 Global Anti-epileptic Drugs Market, by Drug Class, 2016 (US$ Mn)
FIG. 3 Global Anti-epileptic Drugs Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Value Chain Analysis: Global Anti-epileptic Drugs Market
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Hydantoin derivatives (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Iminostilbenes (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Long acting barbiturates (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Succinimides (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Benzodiazepines (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Carbonic anhydrase inhibitors (CAI) (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global GAMA- vinyl – GABA (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Amino acid derivatives (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Monosacharide derivatives (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Others Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 17 U.S. Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 18 Canada Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 19 U.K. Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 20 Germany Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 21 Rest of Europe Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 22 China Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 23 Japan Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Asia Pacific Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 25 Brazil Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 26 Mexico Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Latin America Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 28 GCC Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Middle East and Africa Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Anti-epileptic Drugs Market Portraiture
TABLE 2 Global Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 3 Global Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 North America Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 14 Abide Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Advicenne Pharma SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Alexza Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Argentum Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 GlaxoSmithKline (GSK) plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 GW Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Janssen Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Marinus Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Novartis Pharmaceuticals Corp: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Otsuka Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Takeda Pharmaceutical Company Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 UCB Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Question:

What is the size of Anti-epileptic Drugs Market?

The market for Anti-epileptic Drugs Market is expected to reach USD$ 4.08 Bn in 2025.

What is the Anti-epileptic Drugs Market CAGR?

The Anti-epileptic Drugs Market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Anti-epileptic Drugs Market?

The report is forecasted from 2017 -2025.

What is the base year considered for Anti-epileptic Drugs Market?

The base year of this report is 2016.

Who are the major players in this market?

Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals. are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN